2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder
Alar Pharmaceuticals Inc. (abbreviated as Alar Pharm), a new drug development company focused on long-acting release drug products, has announced that it concluded its End-of-Phase 2 (EOP2) meeting with U.S. Food and Drug Administration (FDA) for ALA-1000 on October 27, 2021. ALA-1000 is a long-acting new drug under development to treat opioid use disorder (OUD) with a particular dosing interval of subcutaneous injection once every three months. Based on the…
Comments Off on 2021/10/28 Alar Pharmaceuticals Inc. Completes Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder
28 . 10 . 2021